18F-FDG-PET and histopathology in 131I-lipiodol treatment for primary liver cancer.

The diagnostic accuracy of 18F-FDG-PET (fluoro-2-deoxyglucose-positron emission tomography) remains questionable for primary hepatocellular carcinoma (HCC) but seems to be more promising for restaging and therapy control. Yet, there are no data on FDG-PET in 131I-lipiodol treatment for primary liver cancer. The aim of this study was to relate baseline FDG-PET findings to histologic data and to assess, for the first time, the role of repetitive FDG-PET imaging for follow-up of 131I-lipiodol treatment. Eighteen (18) patients (16 HCC, 2 cholangiocellular carcinoma; CCC) with 36 treatment courses (up to four per patient) had 35 PET exams, including 18 post-treatment follow-up scans in 10 patients (up to three per patient, one without baseline PET; n = 17). Histopathologic results were available in 15 patients. PET results were retrospectively related to histopathologic type, grading, presence of cirrhosis, and tumor size at baseline and compared with computed tomography (CT) during follow-up. Prior to 131I-lipiodol treatment, 8 patients were PET positive and 9 PET negative. Most of the large HCCs were PET positive and most small tumors PET negative (p < 0.05), despite an overlap below 11 cm. There was no identifiable correlation between PET results and degree of tumor differentiation. Overall, 9 of 10 patients with 17 of 18 follow-up scans showed concordant results with CT. The one discrepant case became PET negative after the first treatment course, despite CT-proven tumor growth (false negative). Patient management was not changed due to PET results. In conclusion, large HCCs were significantly more often PET positive, but there was no correlation with the degree of differentiation. Follow-up PET may be useful if the tumor is first demonstrated to be FDG positive.

Role of FDG-PET in the assessment of survival prognosis in melanoma.

Positron-emission tomography (PET) employing fluorodeoxyglucose (FDG) has proven to be a highly sensitive and specific diagnostic method in the staging and restaging of various neoplasms, including melanoma, complementing morphologic imaging. FDG uptake has been correlated with proliferation rate, and thus, the degree of malignancy of a given tumor (i.e., grading). Consecutively, a relationship of survival prognosis and the extent of tumor burden as well as degree of FDG accumulation--determined by FDG-PET--has been suggested in various tumors. The aim of this study was to assess the potential of fluor-18-FDG-PET in order to evaluate the survival prognosis in melanoma. Patient data (n=95) were retrospectively analyzed, and the results of functional FDG-PET staging was correlated with survival data. Time of staging (diagnosis of primary versus recurrence) had no statistically significant effect on survival prognosis when patients were matched for pertaining node metastasis (NM) stages. Differences in survival were owing to the presence of metastatic disease rather than time of staging. Tumor (T)-stage (T1-T4) alone had no effect on survival prognosis when patients were matched for NM stages. Differences in survival were also due to higher rates of lymph node (LN) and organ metastases in higher T-stages. Detection of LN metastases (N1M0) had a statistically significant and predominant impact on 5-year survival (N0M0 80% versus N1M0 45%; p<0.01). Additional presence of distant metastases in LN-positive patients (N1M1) had only a statistically insignificant further impact on survival (5-year survival in N1M0 45% versus N1M1 29%; p>0.05). Exclusive presence of organ metastases (N0M1) showed a statistically significant drop of survival with a 5-year survival of 61% in N0M1 versus 80% in N0M0, respectively (p<0.03). Further, the combined presence of LN and distant metastases had the worst prognosis (5-year survival in N1M1 29% versus N0M1 61%; p<0.02). Based on a qualitative 4-point scoring system, patients with malignancy-typical FDG uptake showed an overall 5-year survival of 38%, as compared to patients with malignancy-suspicious lesions (71%; p

Sentinel node biopsy as staging tool in a multimodality treatment approach to cancer of the oral cavity and the oropharynx.

OBJECTIVES: Feasibility of sentinel lymph node (SLN) biopsy in head and neck cancer as a staging tool embedded in a multimodality regimen including neoadjuvant intraarterial chemotherapy. STUDY DESIGN AND SETTING: 39 patients with oral and anterior oropharyngeal cancer classified N0 by [18 F]FDG-PET underwent SLN scintigraphy. Selective SLN biopsy without elective neck dissection (ND) was performed, immediately followed by radical resection of the primary tumor. Histopathology included step-serial sections and immunocytochemistry. RESULTS: Lymphoscintigraphy detected 104 spots. In 15 patients there was bilateral drainage. 114 SLN were excised due to additional intraoperative discrimination. 95% of visualised SLN could be removed. Histology was positive in 3 patients (8%), all underwent ND which yielded another positive node in 2 cases. Median observation time was 30 months. Two patients (5%) had a neck relapse in combination with a second primary. CONCLUSIONS: SLN biopsy as only surgical staging tool seems to be feasible. SIGNIFICANCE: Method promises reduction of elective ND and morbidity in N0 patients.

Therapy of hepatocellular cancer with iodine-131-Lipiodol.

Most patients with hepatocellular carcinoma are not eligible for surgery at the time of primary diagnosis. Portal vein thrombosis is frequent and represents a contraindication for transarterial chemoembolisation. Transarterial therapy with iodine-131-Lipiodol is superior to systemic therapy in tumours up to diameters of 5 cm and may be performed even in cases with portal vein thrombosis. Compared to other intraarterial therapy procedures, iodine-131-Lipiodol shows the same efficacy but less side effects.